Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

(2011) J. B. Bussel et al.   BLOOD

Consensus Paper—ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia

(2010) Hannah Tamary et al.   ANNALS OF HEMATOLOGY

Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database

(2010) Mellissa Yong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production

(2009) Diane Nugent et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

(2008) James N. George et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET